Literature DB >> 22679191

Risperidone associated tardive dyskinesia--a less common phenomenon.

Amin Gadit1.   

Abstract

A 51-year-old gentleman was admitted with a history of severe depression with marked agitation in the background of cocaine abuse. He had multiple medical problems like deep vein thrombosis, hepatitis C and tardive dyskinesia. Besides him being on antidepressant medication, risperidone was prescribed by his previous physician for a period of 2 years. Since commencement on this medication, he developed tardive dyskinesia that was never recognised and managed. This side effect caused additional anxiety to the patient and affected his social life. Upon admission, his medications were reviewed, risperidone was gradually withdrawn and procyclidine 2 mg twice daily was added. After being discharged from hospital, he was regularly seen in the out patient clinic. Within 3 months, his tardive dyskinesia improved tremendously, his quality of social life got better and by virtue of this, there was a faster remission in his depression and anxiety symptoms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22679191      PMCID: PMC3176371          DOI: 10.1136/bcr.07.2011.4471

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Tardive dyskinesia with risperidone and anticholinergics.

Authors:  Eiji Suzuki; Michiyuki Obata; Yoshiko Yoshida; Hitoshi Miyaoka
Journal:  Am J Psychiatry       Date:  2002-11       Impact factor: 18.112

2.  New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol.

Authors:  Georges M Gharabawi; Cynthia A Bossie; Young Zhu
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

3.  Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.

Authors:  D V Jeste; J P Lacro; A Bailey; E Rockwell; M J Harris; M P Caligiuri
Journal:  J Am Geriatr Soc       Date:  1999-06       Impact factor: 5.562

4.  Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.

Authors:  Xue-Min Gao; Thomas Cooper; Raymond F Suckow; Carol A Tamminga
Journal:  Neuropsychopharmacology       Date:  2005-11-23       Impact factor: 7.853

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.